Kenya's National Examination Council has migrated over 30 million academic records to the Avalanche blockchain to combat widespread academic certificate forgery. This move replaces an outdated, inefficient system with a decentralized, tamper-proof verification platform that allows instant authentication of academic credentials. The adoption highlights Avalanche's growing institutional use and its role in bridging blockchain technology with real-world applications. This development is expected to enhance trust in academic qualifications and reduce fraud in Kenya's employment and education sectors.
Avalanche blockchain adoption in Kenya is notable. For readers following cryptocurrency markets, here is Pluang's snapshot as of Oct 06, 2026 03:02 WIB: out of 50 major cryptocurrencies, 24 rose and 25 fell. Notable movers include AXS at Rp23.139 with a -5.81% change and 69% buy orders, ADA at Rp4.754 with a +5.48% change and 60% buy orders, and ONE at Rp41 with a -4.00% change and 66% buy orders.
Revvity's stock has surged 56.1% year-to-date, outperforming its industry and the S&P 500, driven by an 11% organic revenue growth in diagnostics, especially in reproductive health and immunodiagnostics. Analysts from William Blair and Zacks have upg...
Levi Strauss & Co. is set to report its Q3 2026 earnings on October 7, with analysts forecasting adjusted earnings of $0.36 per share and revenue of $1.61 billion, marking a 4.5% increase year-over-year. Strong denim demand and growth in Europe, Asia...
On October 5, 2026, five notable stocks experienced double-digit declines. Sphere Entertainment fell 13.6% after a downgrade from Craig-Hallum, while C.H. Robinson dropped 10.9% following its announcement to acquire RXO for $5.8 billion. Velo3D, Boos...
Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...
Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...
